SCHEMBL321562

SCHEMBL321562

CNCC1CCOC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14143341 1.00
SCHEMBL14178768 1.00
Hydrochloric Acid SCHEMBL22230727 0.98
SCHEMBL23710053 0.86
SCHEMBL10154051 0.86
SCHEMBL23710147 0.86
SCHEMBL552779 0.85
Hydrochloric Acid SCHEMBL2106788 0.83 KCNH3 (0.38)
SCHEMBL24951677 0.83 SIGMAR1 (0.41)
SCHEMBL6929311 0.80 DRD4 (0.38)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 209 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180360834-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF CANCER DISEASES BOEHRINGER INGELHEIM INT (DE) 2018-12-20 US claimed
EP-3173084-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF CANCER DISEASES Boehringer Ingelheim International GmbH (DE) 2017-05-31 EP claimed
US-20170112835-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF CANCER DISEASES BOEHRINGER INGELHEIM INT (DE) 2017-04-27 US claimed
US-8586608-B2 Quinazoline derivatives and pharmaceutical compositions containing them BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2013-11-19 US claimed
US-RE43431-E1 Quinazoline derivatives and pharmaceutical compositions containing them BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2012-05-29 US claimed
EP-2340837-A1 Combination treatment of cancer comprising EGFR/HER2 inhibitors Boehringer Ingelheim International GmbH (DE) 2011-07-06 EP claimed
US-20100010023-A1 QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2010-01-14 US claimed
US-20090306101-A1 COMBINATION TREATMENT OF CANCER COMPRISING EGFR/HER2 INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-12-10 US claimed
US-20090306044-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF CANCER DISEASES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-12-10 US claimed
EP-1948180-A1 COMBINATION TREATMENT OF CANCER COMPRISING EGFR/HER2 INHIBITORS Boehringer Ingelheim International GmbH (DE) 2008-07-30 EP claimed
EP-1948179-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF CANCER DISEASES Boehringer Ingelheim International GmbH (DE) 2008-07-30 EP claimed
WO-2007054550-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF CANCER DISEASES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-05-18 WO claimed
WO-2007054551-A1 COMBINATION TREATMENT OF CANCER COMPRISING EGFR/HER2 INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-05-18 WO claimed
US-20060100223-A1 Quinazoline derivatives and pharmaceutical compositions containing them BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2006-05-11 US claimed
US-7019012-B2 Tyrosine inhibitors; antitumor agents; respiratory system disorders BOEHRINGER INGELHEIM INTERNATIONAL PHARMA GMBH & CO. KG (DE) 2006-03-28 US claimed
US-20020173509-A1 Quinazoline derivatives and phamaceutical compositions containing them BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2002-11-21 US claimed
US-20260001846-A1 SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS SERVIER LAB (FR) 2026-01-01 US disclosed
US-12454534-B2 Pyrrolo[2,3-b]pyrazines as HPK1 inhibitor and the use thereof BEONE MEDICINES I GMBH (CH) 2025-10-28 US disclosed
US-5434181-A FOR USE IN AGRICULTURAL CHEMICALS MITSUI TOATSU CHEMICALS, INC. (JP) 1995-07-18 US disclosed
EP-0649845-A1 Furanyl insecticide MITSUI TOATSU CHEMICALS, Inc. (JP) 1995-04-26 EP disclosed